The Alzheimer’s Network (ALZ-NET) is a network of clinicians that will collect information about participants’ treatment and care. The purpose of this study is to enable ALZ-NET to collect long-term data of individuals who are evaluated for or receive treatment with a novel FDA-Approved therapy for Alzheimer's Disease (AD). A novel FDA approved therapy approved therapy for AD is a medication that has been approved by the FDA since 2011 and has Alzheimer's disease listed as an indication with the prescribing instructions.
   
ALZ-NET aims to not only facilitate additional advancements in future AD therapies, but also to identify gaps in effectiveness and safety that are found during the real-world use of already approved therapies. ALZ-NET will follow and record information about people’s health, safety, brain scans, and long-term health outcomes during their regular memory care. It will include people from many different places and backgrounds, which helps include more types of people than those usually in clinical trials. ALZ-NET will not require a specific intervention; it is meant to observe your care and treatment.
   
ALZ-NET aims to be a resource for evidence gathering, information sharing, and education across clinical and research communities to support and improve care of individuals living with Alzheimer’s disease. It is a way for researchers to study certain parts of a disease, how it is diagnosed, or how it is treated, by watching and noting what happens. 
   
If you agree to take part in ALZ-NET, you are agreeing to allow your memory care provider to share collected information about your regular visits until one of the participation end points is met, including but not limited to your withdrawal of consent, stopping care from your memory care provider, or the closure of ALZ-NET. Participation in ALZ-NET does not have a set end date.